earticle

영어

There has been a lot of attention and subsequent business activities around biosimilar in Korea during the past a couple of years. Not only some sizeable Korean pharmaceutical companies but some new players in pharmaceutical/biopharmaceutical sectors took a step in developing biosimilar products and particularly some notable companies widely covered by press have apparently shown aggressive moves to bring their products beyond Korean market. On government side, relatively big financial support was granted to a group of companies developing biosimilar products under the name of "SMART Project". Following these movements, various endeavors by government sector including the foundation of fund to support bio-business are expected to be observed in near future. All these activities around biosimilar business is based on a fundamental assumption that biosimilar could become a national platform as a future growth engine. At this point of time when unprecedented amount of investment is being put into biosimilar business, we need to answer some critical questions to project outlook of biosimilar and ultimately to figure out strategy and action plans to win this game
• Is there going to be a market forbiosimilar and then how big will it be?
• What are drivers and risks of biosimilar business?
• Who are current players and where are they playing in terms of value chain & geography
and what are their core competencies?
• What would be the key success factors in biosimilar business from Korean company’s
perspective?
• What are the effective strategy, commercial model, roles & responsibilities and action plans
for each of Korean companies and Korean government?
IMS Korea will elaborate on current market status, key drivers & risks, difference between
chemical generic & biosimilar and points to be considered by Korean companies. And then
IMS will provide some feasible high-level strategic options for biosimlar commercialization.